| The MAP kinase-interacting kinases (MNKs) as targets in oncology J Xie, JE Merrett, KB Jensen, CG Proud Expert Opinion on Therapeutic Targets, 2019 | 35 | 2019 |
| Design, synthesis and activity of Mnk1 and Mnk2 selective inhibitors containing thieno [2, 3-d] pyrimidine scaffold X Jin, J Merrett, S Tong, B Flower, J Xie, R Yu, S Tian, L Gao, J Zhao, ... European journal of medicinal chemistry 162, 735-751, 2019 | 30 | 2019 |
| Identification of DNA response elements regulating expression of CCAAT/enhancer-binding protein (C/EBP) β and δ and MAP kinase-interacting kinases during early adipogenesis JE Merrett, T Bo, PJ Psaltis, CG Proud Adipocyte 9 (1), 427-442, 2020 | 23 | 2020 |
| Reciprocal signaling between mTORC1 and MNK2 controls cell growth and oncogenesis J Xie, K Shen, AT Jones, J Yang, AR Tee, MH Shen, M Yu, S Irani, ... Cellular and Molecular Life Sciences 78, 249-270, 2021 | 18 | 2021 |
| MAPK-interacting kinase 2 (MNK2) regulates adipocyte metabolism independently of its catalytic activity JE Merrett, J Xie, PJ Psaltis, CG Proud Biochemical Journal 477 (14), 2735-2754, 2020 | 7 | 2020 |
| Control of adipocyte differentiation and metabolism by mitogen-activated protein kinase (MAPK)-interacting kinases (MNKs) JE Merrett University of Adelaide, 2020 | | 2020 |
Christopher ProudDistinguished Fellow, SAHMRIVerified email at sahmri.com
